I look at this as great news for mek inhibitors and EXEL and ARRY ......these r two companies that lead in mek development....mek cause be used in other indication....Though I wish we were out front it still gives mek considerable credibility
BGF this is R. Goulet from twitter....what I find interesting is those bio twitter analysts eg. p. cutcher and minions saying comet is underpowered and comet success is pegged at less than 30%....I remember AF saying this and now he seems positive...not sure #$%$ is going on, but why would EXEL go through all this if they felt that the chances were so low considering they stated prostate as low hanging fruit...I am staying long and adding on dips...and yes this will be taken out quickly if comet goes +
U guys keep saying this....first of all ARRY has 0 products on the market Jazz has 9...granted I have not looked 2 c how much these products take in...if ARRY hits 10, count your blessings....and I 'm a long
Though I to am a long investor here buyoutmoney has no clue what he's talking about.....no chance, it's not even in the discussion for any big bio to purchase ARRY....if any bio is bought it would be exelixis, since they have a wholly owned product with great potential and huge royalties on mek inhibitor cobimetinib with roche...that's a nice looking carrot....ARRY is hinged all on its mek program which is all partnered....everything else in the pimple p2 or higher is a long shot. None of this excites big pharma for a buyout...do your DD
I am buying on any dip....I added more at 6.18 because I liked that this broke the 52 week high and cobimetinib that is partnered with Roche is looking good....Roche is very confident in this compound evidence is seen with the recent increase in additional studies...cobimetinib is not priced in...I even thnIk foretinib has potential
$12-15...it was at 12 after the bone data...it goes right back to its home if pos.
I am here long, quite a few shares but I think honestly it's all coming down to the mek inhibitors.....the rest of the pipe are all long shots